Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Type and rate of clonal evolution vary widely in sarcoma pathogenetic subgroups

Hofvander J et al. Nature Communications 10 Sept. 2018. https://doi.org/10.1038/s41467-018-06098-0

Key clinical point: Sarcomas caused by different pathogenetic mechanisms vary considerably in the rate at which new mutations become predominant and whether nucleotide or chromosome level mutations prevail. Further, marked variation in genetic stability at the single cell level does not necessarily translate into major changes in the tumor stemline

Main finding: The extensive single-cell variation in well-differentiated liposarcoma had minor impact on clonal key amplicons in chromosome 12. Only a few of the single nucleotide variants in well-differentiated liposarcoma were present in more than one lesion, suggesting that such mutations are of little significance in tumor development. Myxoid liposarcoma displays few mutations other than the FUS-DDIT3 fusion, and the primary tumor is genetically sometimes much more complex than its relapses. Sarcomas with complex genomes have a gradual increase of both nucleotide- and chromosome–level mutations, similar to what has been described in carcinomas.

Study details: The study included 20 sarcoma patients from whom 2–5 lesions had been obtained, with 12–306 months between first and last sampling. Cytogenetics, SNP array analysis, and whole-exome sequencing were used to compare chromosome and nucleotide level mutations in 5 patients with amplicon-driven well-differentiated liposarcoma, 9 patients with gene fusion-driven myxoid liposarcoma, and 6 patients with sarcomas with complex genomes (5 myxofibrosarcomas and 1 myoepithelial tumor).

Disclosures: The authors declared no competing interests.

Source: Hofvander J et al. Nature Communications 10 Sept. 2018. https://doi.org/10.1038/s41467-018-06098-0

Citation:

Hofvander J et al. Nature Communications 10 Sept. 2018. https://doi.org/10.1038/s41467-018-06098-0

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

Expanded genetic analyses of myxofibrosarcomas may guide precision therapies, Ogura K et al. Nature Communications; 17 July 2018. https://doi.org/10.1038/s41467-018-03891-9

Malignant tenosynovial giant cell tumors appear to originate from synoviocytes, Al-Ibraheemi A et al. Modern Pathology; 11 Sept. 2018. https://doi.org/10.1038/s41379-018-0129-0

Must Reads in Liposarcoma

Type and rate of clonal evolution vary widely in sarcoma pathogenetic subgroups, Hofvander J et al. Nature Communications 10 Sept. 2018. https://doi.org/10.1038/s41467-018-06098-0

Trabectedin and olaparib show promise in soft-tissue sarcomas, Grignani G et al. The Lancet Oncology 2018; 1360-1371. https://doi.org/10.1016/S1470-2045(18)30438-8

Perioperative chemotherapy not associated with worse survival after distant metastasis in patients with primary localized extremity soft tissue sarcoma, Callegaro D et al. European Journal of Cancer 2018 (105); 19-27. https://doi.org/10.1016/j.ejca.2018.09.028

Nondisease-specific mortality in patients with surgically-treated retroperitoneal sarcomas, Nazzani S et al. European Urology Oncology 2018; 1(4): 346-351. https://doi.org/10.1016/j.euo.2018.05.008

MRI radiomics for predicting histologic grade of soft tissue sarcomas, Zhang Y et al. Academic Radiology 2018; published online Oct. 28 https://doi.org/10.1016/j.acra.2018.09.025